SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas shares sold off sharply after leaked Phase 3 melanoma-vaccine results, despite showing a benefit when combined with Keytruda; traders viewed the data as positive but short of expectations after a steep run-up. The debate centers on whether this was a sell-the-news reaction and overvaluation reset or whether the vaccines results support a recovery.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabets sharp pullback ahead of earnings, alongside reports of analyst downgrades and selling across big tech, is driving discussion. Traders are split between buying the dip on Cloud and AI growth prospects and worrying that search competition, heavy AI spending, or disappointing guidance could deepen the decline.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

A sharp selloff in silver has put SLV under pressure, with traders debating whether higher yields and a stronger dollar are outweighing its traditional safe-haven appeal. Bearish posts focus on further downside and its recent correlation with risk assets, while dip buyers argue that silvers longer-term supply and inflation-hedge case remains intact.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians steep selloff and fresh lows ahead of its quarterly results dominate discussion, with traders focused on whether stronger deliveries and the R2 ramp can offset concerns about cash burn, profitability, and execution. Some expect the results or guidance to spark a rebound, while others remain bearish about the companys ability to scale profitably.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong Q3 results and raised full-year guidance were followed by a sharp selloff, prompting traders to debate whether the decline reflects negative cash flow and heavy investment spending, stretched valuation, or broader weakness in AI-related stocks. Bulls view the drop as an overreaction to growth-related spending, while skeptics question whether earnings can justify the valuation.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is being swept up in a sharp selloff across AI data-center and former Bitcoin-miner stocks, as traders question AI infrastructure demand and worry about high financing costs and project execution. Bears see further downside, while bulls view the decline as an overreaction and point to HUTs data-center buildout and Bitcoin exposure as reasons for optimism.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows rally is drawing attention amid optimism that its enterprise AI agents and governance tools can turn AI adoption into revenue, alongside analyst upgrades and strength in software stocks relative to chipmakers. Traders are positioning ahead of earnings, while others warn that the sharp run-up and volatile price action could give way to profit-taking or a post-report reversal.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce shares are under pressure amid a sharp pullback, with traders debating whether it reflects broader market and sector weakness, higher fuel costs and geopolitical concerns, or profit-taking. Many bullish holders are treating the decline as a buying opportunity and pointing to buybacks and the companys aerospace, defence and SMR prospects, while others expect further losses.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026PR NewswireSOUTH SAN...

Reasons Why Investors Should Consider Betting on Arvinas Stock

ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR NewswireSOUTH SAN FRANCISCO, Calif., Oct. 2, 2026SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire...

EVP & Chief Financial Officer At Rigel Pharmaceuticals Exercises Options Worth $123K

A large exercise of company stock options by Dean Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals (NASDAQ:RIGL) was disclosed in a new SEC filing on September 3, as part of an insider exercise.
Whatread more...

Rigel to Participate in Upcoming September Investor Conferences

Rigel to Participate in Upcoming September Investor Conferences Rigel to Participate in Upcoming September Investor Conferences PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial...

Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer PR Newswire SOUTH SAN...

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

Rigel (RIGL) delivered earnings and revenue surprises of -3.30% and +14.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Rigel Reports Second Quarter 2026 Financial Results

Rigel Reports Second Quarter 2026 Financial Results Rigel Reports Second Quarter 2026 Financial Results PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 4, 2026 Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations...

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results PR Newswire SOUTH SAN FRANCISCO, Calif., July 28, 2026 SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire...

Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?

Bioventus (BVS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Rigel will develop, manufacture, and commercialize Vepdegestrant, which will be sold under the brand name Veppanu.</li><li>Vepannu, developed by Arvinas and Pfizer, received FDA approval earlier this month.</li><li>Arvinas and Pfizer will receive $70 million upfront and an additional $15 million upon completion of certain transition activities.</li></ul>Shares of Rigel Pharmaceuticals, Inc (RIGL) surged more than 15% on Tuesday after investors welcomed a potential growth opportunity tied to the company’s newly signed global licensing deal with Arvinas (ARVS) and Pfizer (PFE) for a breast cancer treatment.According to Koyfin data, short interest in <a href="https://stocktwits.com/symbol/RIGL">RIGL</a> climbed to 22.3% of the float as of May 12, up sharply from 15.5% at the beginning of the year, marking its highest level ever. The company has roughly 18.5 million outstanding shares.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://app.koyfin.com/charts/g/eq-stzcug"><img src="https://news.stocktwits-cdn.com/Rigel_jpg_90c3024bd7.webp" alt="Rigel.jpg"></a>Source: Koyfin<h2 class="st-heading-2">Veppanu To Drive RIGL’s Revenue Growth</h2>Under the agreement, Rigel will develop, manufacture, and commercialize Vepdegestrant, which will be sold under the brand name Veppanu. The drug is the only FDA-approved oral PROteolysis TArgeting Chimera (PROTAC) therapy, a new class of medicines designed to target and break down disease-causing proteins.Arvinas and Pfizer will receive $70 million upfront and an additional $15 million upon completion of certain transition activities. The companies could also receive up to $320 million in future milestone payments.Rigel said Veppanu will become its fourth commercial product and a key driver of future revenue growth as it expands its cancer treatment portfolio.“Veppanu is expected to contribute strong revenue growth in our expanding commercial portfolio, and we believe it has the potential to become a meaningful driver of long-term growth for Rigel,” said Raul Rodriguez, Rigel’s president and CEO.<h2 class="st-heading-2">Vepannu’s Phase 3 Data Shows 43% Fall In Disease Progression Risk</h2>The drug, developed by Arvinas and Pfizer, received FDA<a href="https://stocktwits.com/news-articles/markets/equity/arvn-stock-gains-fda-approval-breast-cancer-drug-pfizer/cZQVgmpReen">&nbsp;approval</a> earlier this month. The regulatory clearance was supported by a Phase 3 study showing that Veppanu reduced the risk of disease progression or death by 43% compared with the comparator cancer drug, Fulvestrant. Patients treated with Veppanu had a median progression-free survival of five months, compared with 2.1 months for Fulvestrant.Following the FDA approval, Arvinas announced plans to partner with a third party to support the drug’s commercial rollout. Veppanu received Fast Track designation from the FDA in 2024, followed by the agency’s acceptance of its New Drug Application (NDA) for review last August.<h2 class="st-heading-2">RIGL Bulls Eyes $50</h2>Retail sentiment for RIGL shares on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.One user expects the stock to climb to $50, a 40% upside from current levels, stating Rigel is no longer “just a company managing a future patent cliff” but is a “growing commercial oncology company.”<stembedurl>https://stocktwits.com/ExtraRun123/message/653075404</stembedurl>Another user called the deal a “potential game-changer.”<stembedurl>https://stocktwits.com/Ou8mycookie/message/653059707</stembedurl>The stock has gained more than 14% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-has-gained-nearly-16-in-a-month-but-wall-street-sees-further-upside/cZXXhJWReiX">NVDA Stock Has Gained Nearly 16% In A Month – But Wall Street Sees Further Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. MRAM and HPAI stocks surged in overnight trading (Image source: Getty Images)

Rigel Pharmaceuticals signed a global licensing deal with Arvinas and Pfizer for an advanced breast cancer treatment.

Arvinas Inc

Pfizer Inc

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Current Price	$48.86
Prev Close	$48.88
Open	$48.97
Dividend Yield	0.00%
50-Day Moving Average	$46.88
Beta	1.25
Avg. Volume	232,868.22
PE Ratio	2.99

52-Week High	$52.24
52-Week Low	$24.95
Market Capitalization	$912.7M
EPS (Annual)	$19.48
Price to Book	2.14
Revenue Per Employee	$1.69M

Feed

News

Sentiment

Earnings

Fundamentals

Info

RIGL Fundamentals